Previous close | 19.00 |
Open | 19.80 |
Bid | 13.00 |
Ask | 23.00 |
Strike | 720.00 |
Expiry date | 2025-12-19 |
Day's range | 19.00 - 19.80 |
Contract range | N/A |
Volume | |
Open interest | 25 |
Regeneron (REGN) and Lexicon (LXRX) are in the spotlight following drug approval and regulatory update, respectively.
REGN's oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).
HRMY vs. REGN: Which Stock Is the Better Value Option?